Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831766 · ClinicalTrials.gov registry record · Phase 1
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT00831766 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 51 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00831766, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to: * Test the safety of the research study drug, lenalidomide, when given with Idarubicin and Cytarabine * See how many respond to combination treatment with lenalidomide, Idarubicin and Cytarabine * See how long people respond to this combination therapy * See how long people live after being treated with this combination of drugs
Conditions Studied
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Lenalidomide (Revlimid®)
Study Locations (2)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Ohio
- Cleveland Clinic - Taussig Cancer Institute - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-06-25 |
| Est. Completion | 2020-11-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831766
The ClinicalTrials.gov registry entry for NCT00831766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (56% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Cytarabine is the first listed.
NCT00831766 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT00831766 about?
NCT00831766 is a clinical study titled "Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)". The purpose of this study is to: * Test the safety of the research study drug, lenalidomide, when given with Idarubicin and Cytarabine * See how many respond to combination treatment with lenalidomide, Idarubicin and Cytarabine * See how long people respond to this combination therapy * See how lon...
What is the current status of trial NCT00831766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2009-06-25. Estimated completion is 2020-11-16.
What conditions does trial NCT00831766 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome.
What interventions are being tested in trial NCT00831766?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), Lenalidomide (Revlimid®) (DRUG).
Who is sponsoring clinical trial NCT00831766?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00831766 being conducted?
This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.